JDRF and Eli Lilly signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate the insulin-producing cells destroyed by the disease. The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. This research is an example of regenerative medicine...